Monte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,176 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,176 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total value of $41,344.00. Following the completion of the sale, the chief operating officer directly owned 62,371 shares in the company, valued at approximately $1,185,049. The trade was a 3.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $43,500.00.

Monte Rosa Therapeutics Stock Performance

Monte Rosa Therapeutics stock traded down $0.09 during midday trading on Thursday, reaching $18.32. 2,507,725 shares of the company were exchanged, compared to its average volume of 1,308,502. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -12.38 and a beta of 1.60. The firm’s 50-day simple moving average is $18.60 and its 200-day simple moving average is $18.47. Monte Rosa Therapeutics, Inc. has a 1 year low of $4.12 and a 1 year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The firm had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. On average, analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC acquired a new position in shares of Monte Rosa Therapeutics during the 4th quarter valued at $30,000. Russell Investments Group Ltd. acquired a new stake in Monte Rosa Therapeutics in the 3rd quarter valued at $32,000. Lazard Asset Management LLC increased its holdings in Monte Rosa Therapeutics by 42.9% in the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after purchasing an additional 3,262 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares during the period. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Analyst Upgrades and Downgrades

GLUE has been the subject of a number of analyst reports. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Guggenheim lowered their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. boosted their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $32.50.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.